Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial

Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial

Background: Angiotensin receptor blockers (ARBs), such as telmisartan, have been postulated to treat Covid-19-induced lung inflammation. Methods: This is a parallel-group, randomized, two-arm, open-label, adaptive, multicenter superiority trial with 1:1 allocation ratio. Participants included patien...

Full description

Bibliographic Details
Main Authors: Mariano Duarte, Facundo Pelorosso, Liliana N. Nicolosi, M. Victoria Salgado, Héctor Vetulli, Analía Aquieri, Francisco Azzato, Marcela Castro, Javier Coyle, Ignacio Davolos, Ignacio Fernandez Criado, Rosana Gregori, Pedro Mastrodonato, María C. Rubio, Sergio Sarquis, Fernando Wahlmann, Rodolfo P. Rothlin
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:EClinicalMedicine
Subjects:
Covid-19
ARB
Telmisartan
ACE2
Online Access:http://www.sciencedirect.com/science/article/pii/S258953702100242X

Similar Items

Similar Items